Postpartum Depression Market is Expected to Witness Significant Growth by 2036 Owing to the Emergence of Novel Neuroactive Therapies | DelveInsight

The market dynamics for Postpartum Depression (PPD) are witnessing steady growth driven by increasing awareness regarding maternal mental health, improved screening and diagnosis practices, rising disease burden, and the growing adoption of targeted neuroactive therapies. Additionally, the launch of emerging therapies such as Luvesilocin (Reunion Neuroscience), NORA520 (TWi Biotechnology), LPCN 1154 (Lipocine), and others will further fuel the market growth.

DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Postpartum Depression Market Insights, Epidemiology, and Market Forecast - 2036." This comprehensive report provides an in-depth understanding of Postpartum Depression, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Key Takeaways from the Postpartum Depression Market
• The market size for Postpartum Depression in the 7MM was approximately USD 238 million in 2022 and is expected to grow significantly by 2036.
• According to DelveInsight estimates, the Postpartum Depression market in the 7MM is projected to reach nearly USD 2.7 billion by 2036.
• The United States accounted for the highest Postpartum Depression market size in the 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
• DelveInsight's analysis indicates that the total diagnosed prevalent cases of maternal PPD in the 7MM were approximately 1.3 million in 2025 and are expected to rise during the forecast period.
• Among the 7MM, the United States accounted for the highest diagnosed prevalent cases of maternal PPD in 2025, with approximately 700,000 cases.
• In 2025, the diagnosed prevalent cases of maternal PPD were highest in the US, contributing around 60% of total cases across the 7MM, followed by EU4 and the UK with nearly 30%, while Japan accounted for approximately 10%.
• According to secondary research, approximately 13.7% of women in the United States experience moderate-to-severe depressive symptoms during the postpartum period.
• Secondary research indicates that in Japan, PPD affects approximately 14.3% of women at one month after childbirth.
• Leading Postpartum Depression companies, such as Sage Therapeutics, Biogen, Reunion Neuroscience, TWi Biotechnology, Lipocine, and others, are developing innovative therapies that can potentially transform the Postpartum Depression treatment market in the coming years.
• The promising Postpartum Depression therapies in clinical trials include Luvesilocin (RE104), NORA520, LPCN 1154, and others.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Postpartum Depression Market
• Rising Awareness and Diagnosis Rates: Increasing awareness regarding maternal mental health disorders, expanding screening initiatives, and growing recognition of postpartum psychiatric conditions are contributing to rising diagnosis rates of PPD globally.
• Growing Demand for Effective Pharmacological Therapies: Current treatment approaches include antidepressants such as selective serotonin reuptake inhibitors (SSRIs), GABA-A receptor modulators, and supportive therapies. Approved therapies such as ZURZUVAE are improving treatment accessibility and patient outcomes.
• Increasing Preference for Personalized and Rapid-acting Therapies: Novel neuroactive steroid therapies and targeted hormonal approaches are gaining attention for their ability to provide faster symptom relief and improve maternal functioning compared to conventional antidepressants.
• Expansion of Non-pharmacological Interventions: Psychosocial therapies, cognitive behavioral therapy (CBT), interpersonal therapy, psychodynamic therapy, exercise, and supportive behavioral interventions are increasingly utilized to improve overall patient care and treatment adherence.

Postpartum Depression Competitive Landscape
• Several Postpartum Depression therapies in development include Luvesilocin (RE104) by Reunion Neuroscience, NORA520 by TWi Biotechnology, and LPCN 1154 by Lipocine.
• These therapies target neuroactive and hormonal pathways involved in mood regulation and emotional functioning, aiming to improve depressive symptoms, enhance treatment accessibility, and address key unmet needs associated with Postpartum Depression.

Discover more about therapies set to grab major Postpartum Depression market share @ https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Postpartum Depression Market
• In February 2026, the US FDA granted Breakthrough Therapy designation (BTD) to luvesilocin for the treatment of Postpartum Depression.
• In February 2026, Lipocine announced that the last patient completed the final study visit in a confirmatory Phase III trial evaluating LPCN 1154 for PPD, with topline results expected in early April 2026.
• In January 2026, Reunion Neuroscience reported full data from the RECONNECT Phase II clinical trial of RE104 for the treatment of PPD at the ACNP Annual Meeting.
• In November 2025, TWi Biotechnology reported results from a Phase II clinical trial of NORA520 for postpartum depression.
• In September 2025, the European Commission granted EU marketing authorization for zuranolone for PPD.
• In August 2025, the MHRA approved zuranolone for the treatment of postnatal depression in adults following childbirth.
• In April 2025, the US FDA withdrew approval of ZULRESSO (brexanolone) following a request from Sage Therapeutics to discontinue its marketing.

What is Postpartum Depression?
Postpartum Depression (PPD) is a mood disorder occurring after childbirth, characterized by emotional disturbances and neurobiological changes leading to symptoms such as sadness, anxiety, irritability, impaired functioning, and difficulty performing daily activities. The condition significantly affects maternal well-being and quality of life. In severe cases, PPD-related psychosis may occur, involving hallucinations, delusions, and impaired perception of reality. Early diagnosis and effective treatment are essential to reduce disease burden and improve maternal and infant outcomes.

Postpartum Depression Epidemiology Segmentation
The Postpartum Depression epidemiology section provides insights into the historical and current Postpartum Depression patient pool and forecasted trends for the leading markets. The Postpartum Depression market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets segmented into:
• Total Diagnosed Prevalent Cases of Maternal PPD
• Country-specific Diagnosed Prevalent Cases of Maternal PPD
• Age-specific Diagnosed Prevalent Cases of Maternal PPD
• Treatment-eligible Cases of PPD
• Severity-specific Burden of Postpartum Depression

Scope of the Postpartum Depression Market Report
• Therapeutic Assessment: Postpartum Depression current marketed and emerging therapies
• Postpartum Depression Market Dynamics: Key Market Forecast Assumptions of Emerging PPD Drugs and Market Outlook
• Key Companies: Sage Therapeutics, Biogen, Reunion Neuroscience, TWi Biotechnology, Lipocine, and others
• Key Therapies: ZURZUVAE (zuranolone), Luvesilocin (RE104), NORA520, LPCN 1154, and others
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Postpartum Depression Market Access and Reimbursement

Table of Contents
1. Postpartum Depression Market Report Introduction
2. Executive Summary for Postpartum Depression
3. SWOT Analysis of Postpartum Depression
4. Postpartum Depression Market Overview at a Glance
5. Disease Background and Overview of Postpartum Depression
6. Postpartum Depression Epidemiology and Patient Population
7. Country-Specific Patient Population of Postpartum Depression
8. Postpartum Depression Current Treatment and Medical Practices
9. Postpartum Depression Unmet Needs
10. Postpartum Depression Emerging Therapies
11. Postpartum Depression Market Outlook
12. Country-Wise Postpartum Depression Market Analysis (2022-2036)
13. Postpartum Depression Market Access and Reimbursement of Therapies
14. Postpartum Depression Market Drivers
15. Postpartum Depression Market Barriers
16. Postpartum Depression Appendix
17. Postpartum Depression Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

To know more about Postpartum Depression companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.

This release was published on openPR.